---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000120"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:11:19.932542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali Q1 net loss $101.8M, cash $1.43B; reports pipeline progress and $500M PIPE

## Summary
- Net loss $101.8M vs $109.8M YoY; zero collaboration revenue vs $35.1M in Q1 2023.
- R&D expense $107.0M, down from $128.8M; G&A $25.2M, down from $27.1M.
- Completed $500M PIPE financing in February; raised cash to $1.43B.
- Tividenofusp alfa (MPS II) shows sustained biomarker normalization; FDA may consider accelerated path.
- Phase 1/2 for DNL126 (MPS IIIA) dosed; Phase 2/3 COMPASS enrollment expected to complete in 2024.

## SEC filing metadata
- accession: 0001714899-24-000120
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/0001714899-24-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/dnli-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000120
- JSON: https://secwatch.observer/filing/0001714899-24-000120.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000120.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported the first quarter ended March 31, 2024 results: revenue There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended, net income Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter.
  - Period: the first quarter ended March 31, 2024
  - Revenue: There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended
  - Net income: Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter
  - Result: reported results
  source text: Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter ended March 31, 2023. There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/0001714899-24-000120-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.